Market Highlights:
Barlow’s Syndrome is a condition in which there is an
abnormality of the mitral valve of the heart. It is a condition in which the
leaflets of the mitral valve swell into the left atrium of the heart as the valve
closes during ventricular contraction. This abnormality prevents the valve from
closing correctly, which causes it to leak.
The global Barlow’s Syndrome market is expected to
grow at a CAGR of 9% during the forecast period.
Regional Analysis
The Americas dominate the global Barlow’s Syndrome
market owing to the rising geriatric population, increasing genetic disorders,
and increasing number of injuries leading to infections. The Americas are
further segmented into North America and South America. North America holds the
largest market is owing to increasing number of geriatric population, rising
number of cardiovascular disorders, and growing population. Additionally, a
rising number of market players launching newer products, technological
advancements, and market players wanting to expand their foothold is likely to
drive the growth of the Barlow’s Syndrome market in the North American region.
For instance, according to the National Centre for Chronic Disease Prevention
(CDC), in 2015 around 630,000 Americans died of cardiovascular disorders.
Request
For Sample Report: https://www.marketresearchfuture.com/sample_request/5596
Europe accounts for the second largest market due to
rising cardiovascular diseases, increasing funds and increasing healthcare
expenditure. For instance, according to the Eurostat, Germany incurred
healthcare expenditure over EUR 321 billion in 2014. According
to European Society of Cardiology (ESC), around Euro 196 billion was spend for
CVD. Germany, France, and the U.K hold a significant share of the market due to
increasing demand for technologically advanced devices and increasing awareness
in terms of rare diseases, and rising overall growth of the medical device
industry.
The Asia Pacific is the fastest growing Barlow’s
Syndrome market across the globe, whose growth is attributed to the rising
geriatric population, increasing prevalence cardiovascular diseases, and
rapidly developing economies. For instance, according to ESCAPE (Economic and
Social Commission for Asia and the Pacific), in the year 2016, approximately
12.4% of the population was 60 years and older, and is projected to increase to
1.3 billion people by 2050. Additionally, increasing healthcare expenditure and
demand for new treatment options for rare diseases fuel the market growth.
India and China are the major contributors to the market growth due to the
rapid development of healthcare sector and increasing healthcare expenditure in
these regions and increasing demand for diagnostic services.
On the other hand, the Middle East & Africa is
expected to witness limited growth due to limited access to the healthcare
resources and lack of awareness about rare diseases. In the Middle East, the
growth of the market is driven by increasing availability of new diagnostic and
treatment methods for various chronic diseases.
Access Report Details @ https://www.marketresearchfuture.com/reports/barlow-syndrome-market-5596
Segmentation
The global Barlow’s Syndrome market is segmented on
the basis of type, treatment, diagnosis, and end-users.
On the basis of the type, the market is segmented as
mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation.
On the basis of the treatment, the market is
segmented into medications and surgery. Medications are further sub-segmented
to beta-blockers and calcium blockers. The beta blockers further sub-segmented
to atenolol and metoprolol. The calcium blockers are further sub-segmented into
Verapamil and Diltiazem.
On the basis of the diagnosis, the market is
segmented into X-ray, electrocardiogram, and echocardiogram.
On the basis of the end user, the market is segmented
into hospitals & surgical centers, research institutes, and specialty
clinics.
Key Players
Some of the key
players in the barlows syndrome market are Abbott, Medtronic, Edward
Lifesciences Corporation, CryoLife, Inc., Boston Scientific Corporation, Micro
Interventional Devices, Inc., Lepu Medical Technology Co., Ltd Neovasc, Inc.,
Sorin Group, TTK HealthCare, JenaValve Technology, Inc. among others.
No comments:
Post a Comment